Daily Coverage ARDS SNOWMASS 2016


Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

  • Bookmark
  • Share this Video

Protocol T 2-Year Data

by Neil Bressler, MD, Tim Murray, MD

Tim Murray, MD, MBA, sits down with Tim Murray, MD, MBA, to talk about new findings from the DRCR.net Protocol T study. The 1-year results from this clinical trial showed that patients with 20/50 or worse baseline visual acuity who received aflibercept gained more letters than patients who received ranibizumab or bevacizumab. Drs. Murray and Bressler discuss the recently released 2-year study results, and whether aflibercept is still the best option for patients with poor visual acuity at baseline.

5,326 video views since .
32,546 total series views.

Comments (0)